Castle Biosciences CEO sells $512k in stock

Derek J. Maetzold, CEO of Castle Biosciences, sold 14,496 shares of the company's stock on September 21, 2026, according to wire reports. The transaction, executed under a pre-approved Rule 10b5-1 plan, amounted to $512,201, with the sales executed at an average price of $35.334 per share. Maetzold personally disposed of 8,580 shares, while 3,198 and 2,718 shares were sold indirectly through trusts established for his descendants and other beneficiaries.

The sale coincided with a significant rise in CSTL shares, which have increased by 58% over the past year and 52% in the last six months, currently trading at $35.81. Despite being labeled as overvalued by investing professionals, the CEO clarified that he also repurchased 8,580 shares through stock options, exercising them at $2.39 per share.

Following the sale, Maetzold now owns 21,479 shares directly and maintains additional holdings through various trusts. Castle Biosciences recently reported second-quarter results that met market expectations with both profit and revenue surpassing forecasts. The company's adjusted loss per share was 7 cents, compared to the expected 40-cent loss, and revenue reached $103.5 million, exceeding the predicted $86.4 million.

The firm also boosted its full-year sales guidance. In response to the positive performance, BTIG upgraded its price target for Castle Biosciences from $40 to $44, maintaining a Buy rating. The company's strong market performance, particularly in the TissueCypher franchise, which saw a 63% year-over-year increase in volumes and 28% growth in the previous quarter, is credited for these achievements.